Inhibrx Announces Participation in Upcoming Scientific Conference [Yahoo! Finance]
Inhibrx Announces Participation in Upcoming Scientific Conference
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight [Yahoo! Finance]
Inhibrx Biosciences (NASDAQ:INBX) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too [Seeking Alpha]